QMDT: AI 评分 57/100 — AI 分析 (4月 2026)

Quick-Med Technologies, Inc. is a life sciences company focused on developing and commercializing proprietary technologies in the medical and consumer healthcare markets. Their core technologies include NIMBUS, Stay Fresh, and MultiStat, targeting antibacterial and skin therapy applications.

Key Facts: AI Score: 57/100 Sector: Healthcare

公司概况

概要：

Quick-Med Technologies, Inc. operates in the specialty drug manufacturing sector, focusing on antimicrobial and hemostatic technologies. The company's NIMBUS, Stay Fresh, and MultiStat platforms target diverse applications in healthcare, textiles, and personal care, serving both government and commercial clients with specialized biomedical solutions.

QMDT是做什么的？

Founded in 1997 and headquartered in Gainesville, Florida, Quick-Med Technologies, Inc. is a life sciences company dedicated to the research, development, and commercialization of proprietary technologies aimed at the medical and consumer healthcare markets. The company specializes in creating innovative biomedical products and devices with a focus on antibacterial applications. Quick-Med's core technologies include the Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers exhibiting antimicrobial and hemostatic properties suitable for various applications. Additionally, they offer Stay Fresh, a chemical formulation designed for textiles, providing durable antimicrobial protection against a broad spectrum of bacteria. Their MultiStat technology represents a collection of patented methods and compounds geared towards advanced skin therapy applications. Quick-Med Technologies serves a diverse clientele, including government agencies, healthcare and medical organizations, apparel and textile manufacturers, and personal care companies, providing them with specialized solutions based on their unique technology platforms. The company's focus on innovation and specialized applications positions it within the niche market of advanced antimicrobial and hemostatic technologies.

QMDT的投资论点是什么？

Quick-Med Technologies, Inc. presents a speculative investment opportunity within the specialty drug manufacturing sector. The company's proprietary NIMBUS, Stay Fresh, and MultiStat technologies offer potential for growth in diverse markets, including healthcare, textiles, and personal care. With a negative P/E ratio of -0.02 and a negative profit margin of -76.8%, the company's financial performance indicates it is not currently profitable. A gross margin of 69.8% suggests strong potential profitability if sales volume increases. Key catalysts include successful commercialization of their technologies and partnerships with larger industry players. However, the company's small size (5 employees) and OTC market listing introduce significant risks related to liquidity and operational scalability. The beta of -39.80 suggests an inverse correlation with the market, but this may be unreliable due to the company's limited trading volume.

QMDT在哪个行业运营？

Quick-Med Technologies operates within the specialty and generic drug manufacturing industry, characterized by intense competition and stringent regulatory requirements. The market is driven by an increasing demand for advanced antimicrobial and hemostatic solutions across healthcare, textiles, and personal care sectors. Companies like Quick-Med differentiate themselves through proprietary technologies and specialized applications. The industry is subject to evolving regulatory standards and pricing pressures, requiring companies to continuously innovate and adapt to maintain competitiveness. The overall drug manufacturing industry is projected to grow, driven by aging populations and increasing healthcare expenditure.

Drug Manufacturers - Specialty & Generic

Healthcare

QMDT有哪些增长机遇？

Expansion into the Healthcare Market: Quick-Med's NIMBUS technology, with its antimicrobial and hemostatic properties, can be further developed for wound care and surgical applications. The global wound care market is projected to reach $22 billion by 2028, presenting a significant opportunity for Quick-Med to capture market share through strategic partnerships and product innovation. Timeline: 2-3 years for product development and regulatory approvals.
Penetration of the Textile Industry: The Stay Fresh formulation offers a durable antimicrobial solution for textiles, addressing the growing demand for hygienic and odor-resistant apparel. The global antimicrobial textiles market is estimated at $10 billion, with increasing adoption in sportswear, healthcare garments, and home textiles. Quick-Med can expand its market presence through collaborations with textile manufacturers and brands. Timeline: 1-2 years for partnership development and product integration.
Development of Advanced Skin Therapy Products: The MultiStat technology can be leveraged to create innovative skin therapy products targeting various dermatological conditions. The global skin therapy market is projected to reach $40 billion by 2027, driven by increasing consumer awareness and demand for effective skincare solutions. Quick-Med can focus on developing niche products with unique formulations and clinical validation. Timeline: 2-3 years for product development and clinical trials.
Strategic Partnerships with Government Agencies: Quick-Med can pursue collaborations with government agencies to develop and supply antimicrobial solutions for defense and public health applications. Government contracts offer stable revenue streams and opportunities for long-term growth. The company can leverage its NIMBUS technology to address specific needs in areas such as wound care and infection control. Timeline: Ongoing, with continuous engagement and proposal submissions.
Licensing and Technology Transfer: Quick-Med can generate revenue by licensing its proprietary technologies to other companies in the healthcare, textile, and personal care industries. Licensing agreements provide a low-risk approach to expanding market reach and generating royalty income. The company can focus on identifying potential licensees with complementary capabilities and market access. Timeline: Ongoing, with continuous evaluation of licensing opportunities.

Gross Margin of 69.8% indicates strong potential profitability if sales volume increases.
Negative P/E ratio of -0.02 reflects current lack of profitability.
Profit Margin of -76.8% indicates significant losses relative to revenue.
The company has 5 employees, highlighting its small size and potential operational constraints.
Beta of -39.80 suggests an inverse correlation with the market, but may be unreliable due to limited trading volume.

QMDT提供哪些产品和服务？

Develop proprietary antimicrobial technologies.
Create hemostatic products for medical applications.
Formulate antimicrobial solutions for textiles.
Research and develop skin therapy products.
Serve government agencies with specialized solutions.
Cater to healthcare and medical companies.
Provide solutions for the apparel and textile industry.
Offer products for the personal care market.

QMDT如何赚钱？

Develop and patent proprietary technologies in the antimicrobial and hemostatic fields.
Commercialize these technologies through direct sales to government agencies and healthcare providers.
License technologies to companies in the textile and personal care industries.
Generate revenue through product sales, licensing fees, and royalty agreements.

Government agencies requiring antimicrobial solutions.
Healthcare and medical companies seeking advanced wound care products.
Apparel and textile manufacturers looking for antimicrobial fabrics.
Personal care companies developing skin therapy products.

Proprietary Technologies: Patented NIMBUS, Stay Fresh, and MultiStat technologies provide a competitive edge.
Specialized Expertise: Focus on antimicrobial and hemostatic solutions creates a niche market position.
Established Relationships: Existing relationships with government agencies and healthcare providers offer a stable customer base.

什么因素可能推动QMDT股价上涨？

Upcoming: Potential FDA approval for new medical applications of NIMBUS technology (Timeline: 1-2 years).
Ongoing: Expansion of licensing agreements for Stay Fresh formulation in the textile industry.
Ongoing: Development of strategic partnerships with larger pharmaceutical companies for commercialization.
Upcoming: Publication of clinical trial results for MultiStat technology in skin therapy (Timeline: 6-12 months).

QMDT的主要风险是什么？

Ongoing: Limited financial resources and negative profitability.
Potential: Intense competition from larger pharmaceutical and healthcare companies.
Potential: Stringent regulatory requirements and lengthy approval processes.
Ongoing: OTC market listing introduces liquidity and regulatory risks.
Potential: Dependence on key personnel and potential loss of intellectual property.

QMDT的核心优势是什么？

Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
Potential for diverse applications in healthcare, textiles, and personal care.
Existing relationships with government agencies.
High gross margin (69.8%) indicates potential for profitability.

QMDT的劣势是什么？

Small size and limited resources (5 employees).
Negative profit margin (-76.8%) indicates significant losses.
OTC market listing introduces liquidity and regulatory risks.
Limited brand recognition and market presence.

QMDT有哪些机遇？

Expansion into the wound care market with NIMBUS technology.
Penetration of the antimicrobial textiles market with Stay Fresh formulation.
Development of advanced skin therapy products with MultiStat technology.
Strategic partnerships with larger industry players for commercialization.

QMDT面临哪些威胁？

Intense competition from larger pharmaceutical and healthcare companies.
Stringent regulatory requirements and lengthy approval processes.
Pricing pressures and reimbursement challenges.
Potential for technological obsolescence.

QMDT的竞争对手是谁？

Can-Fite BioPharma Ltd — Focuses on autoimmune and inflammatory diseases. — (CANQF)
CV Holdings, Inc. — Diversified holding company with healthcare interests. — (CVHIF)
Digene Corporation — Specializes in diagnostic tests for women's health (acquired by Qiagen). — (DGEN)
Emge Corp. — Unknown - insufficient data to determine business focus. — (EMGE)
NemaRx, Inc. — Focuses on developing therapies for neurological disorders. — (NMXS)

Key Metrics

MoonshotScore: 57/100

Company Profile

CEO: Gregory S. Schultz
Headquarters: Gainesville, US
Employees: 5
Founded: 2002

AI Insight

AI analysis pending for QMDT

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Quick-Med Technologies, Inc. do?

Quick-Med Technologies, Inc. is a life sciences company focused on developing and commercializing proprietary technologies in the medical and consumer healthcare markets. It specializes in biomedical products and devices for antibacterial applications. Their core technologies include NIMBUS (antimicrobial polymers), Stay Fresh (antimicrobial textile formulation), and MultiStat (skin therapy compounds). The company serves government agencies, healthcare providers, apparel manufacturers, and personal care companies, aiming to provide innovative solutions in infection control and skin health.

What do analysts say about QMDT stock?

As of March 17, 2026, there is limited analyst coverage available for Quick-Med Technologies, Inc. due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-0.02) and profit margin (-76.8%), reflect the company's current lack of profitability. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. The company's growth potential hinges on successful commercialization of its proprietary technologies.

What are the main risks for QMDT?

The main risks for Quick-Med Technologies, Inc. include its limited financial resources, negative profitability, and OTC market listing. The company faces intense competition from larger pharmaceutical and healthcare companies and is subject to stringent regulatory requirements. Liquidity is a significant concern due to low trading volume, and there is a risk of dilution if the company issues new shares. Investors should carefully consider these risks before investing in QMDT.